S090 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Sutro Biopharma Inc

Watchlist Manager

Watchlist

Price: 21.6 EUR 4.85% Market Closed

Market Cap: €184m

	Sutro Biopharma Inc F:S090	US
F	Fuchs Se DUS:FPE3	DE
G	GFT Technologies SE XHAM:GFT	DE
	Hudson Pacific Properties Inc F:HP9	US
M	Mitek Systems Inc F:MKQ	US
	Largo Inc F:LR8	CA
	Liberty Broadband Corp NASDAQ:LBRDA	US
	Towa Corp TSE:6315	JP

Profitability Summary

Sutro Biopharma Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-87%

Negative 3Y Average Operating Margin

-168%

Operating Margin is Increasing

-279% > -87%

Negative Net Margin

-154%

Negative 3Y Average Net Margin

-194%

Net Margin is Increasing

-251% > -154%

Negative Free Cash Flow Margin

-153%

Negative 3Y Average Free Cash Flow Margin

-180%

Declining Free Cash Flow Margin

-100% > -153%

Exceptional ROE

331%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-242%

Declining ROIC

-147% > -177%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.